Medicare AdvantageCoverageMedium impact
MA08.028k, Abatacept (Orencia®) for Injection for Intravenous Use
Independence Blue Cross·Rheumatology, Internal Medicine, Family Medicine·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.028k for Abatacept (Orencia®) intravenous injection has been updated with changes effective October 1, 2025. This affects billing and coverage requirements for this rheumatoid arthritis medication administered via IV infusion.
Action Required
By October 1, 2025: Billing team must review updated Medicare Advantage coverage criteria for Abatacept (Orencia®) IV injections. Access the full policy at the provided URL to identify any new prior authorization, documentation, or billing requirements. Update billing procedures and inform providers of any changes to coverage criteria or administration requirements.